Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $7.5 million.

  • Biodesix's Shares Outstanding (Weighted Average) rose 252.9% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 252.9%. This contributed to the annual value of $129.7 million for FY2024, which is 5791.65% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's Shares Outstanding (Weighted Average) is $7.5 million, which was up 252.9% from $146.7 million recorded in Q2 2025.
  • Biodesix's 5-year Shares Outstanding (Weighted Average) high stood at $146.7 million for Q2 2025, and its period low was $2.5 million during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $42.1 million (2022), whereas its average is $64.1 million.
  • Per our database at Business Quant, Biodesix's Shares Outstanding (Weighted Average) skyrocketed by 1009310.34% in 2021 and then crashed by 9082.29% in 2024.
  • Biodesix's Shares Outstanding (Weighted Average) (Quarter) stood at $27.4 million in 2021, then soared by 53.86% to $42.1 million in 2022, then soared by 95.03% to $82.1 million in 2023, then soared by 57.92% to $129.7 million in 2024, then crashed by 94.22% to $7.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $7.5 million for Q3 2025, versus $146.7 million for Q2 2025 and $146.5 million for Q1 2025.